18285065. ANTI-ARA H 2 ANTIBODIES AND USES THEREOF simplified abstract (The General Hospital Corporation)
Contents
- 1 ANTI-ARA H 2 ANTIBODIES AND USES THEREOF
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 ANTI-ARA H 2 ANTIBODIES AND USES THEREOF - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
ANTI-ARA H 2 ANTIBODIES AND USES THEREOF
Organization Name
The General Hospital Corporation
Inventor(s)
Sarita U. Patil of Newton MA (US)
ANTI-ARA H 2 ANTIBODIES AND USES THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 18285065 titled 'ANTI-ARA H 2 ANTIBODIES AND USES THEREOF
Simplified Explanation
The invention provides anti-Ara h 2 antibodies (e.g., an anti-Ara h 2 neutralizing antibody) and methods of using the same, e.g., for treating and/or preventing peanut allergy or sensitivity. Also provided herein are anti-Ara h 2 antibodies and methods of using the same, e.g., for diagnostics and methods of monitoring peanut oral immunotherapy. Combinations of anti-Ara h 2 antibodies for use in determining a treatment response of an individual with a peanut allergy to peanut exposure are also provided. Methods for assessing a treatment response of an individual with a peanut allergy to peanut exposure are included.
- Anti-Ara h 2 antibodies can be used to treat and prevent peanut allergy or sensitivity.
- These antibodies can be used for diagnostics and monitoring peanut oral immunotherapy.
- Combinations of anti-Ara h 2 antibodies can help determine treatment responses to peanut exposure in individuals with peanut allergies.
Potential Applications
The technology can be applied in the medical field for the treatment and management of peanut allergies. It can also be used in diagnostic settings to assess and monitor responses to peanut exposure.
Problems Solved
This technology addresses the need for effective treatments for peanut allergies and provides a method for monitoring and evaluating treatment responses in individuals with peanut allergies.
Benefits
The use of anti-Ara h 2 antibodies can potentially improve the quality of life for individuals with peanut allergies by offering a targeted treatment option. It also allows for personalized monitoring of treatment responses.
Potential Commercial Applications
The technology could be valuable for pharmaceutical companies developing treatments for peanut allergies. Diagnostic companies could also benefit from incorporating these antibodies into their testing kits.
Possible Prior Art
Prior research may have explored the use of antibodies in treating allergies, but specific anti-Ara h 2 antibodies for peanut allergy treatment may be a novel development.
Unanswered Questions
How effective are the anti-Ara h 2 antibodies compared to existing treatments for peanut allergies?
The article does not provide a direct comparison of the effectiveness of anti-Ara h 2 antibodies with other treatments for peanut allergies. Further studies or clinical trials may be needed to address this question.
Are there any potential side effects or limitations associated with the use of anti-Ara h 2 antibodies for peanut allergy treatment?
The potential risks or drawbacks of using anti-Ara h 2 antibodies are not discussed in the article. Additional research or data may be necessary to evaluate the safety profile of these antibodies.
Original Abstract Submitted
The invention provides anti-Ara h 2 antibodies (e.g., an anti-Ara h 2 neutralizing antibody) and methods of using the same, e.g., for treating and/or preventing peanut allergy or sensitivity. Also provided herein are anti-Ara h 2 antibodies and methods of using the same, e.g., for diagnostics and methods of monitoring peanut oral immunotherapy. Also provided are combinations of anti-Ara h 2 antibodies for use in determining a treatment response of an individual with a peanut allergy to peanut exposure. Also provided are methods for assessing a treatment response of an individual with a peanut allergy to peanut exposure.
